Panelists from Aspen Neuroscience, Notch Therapeutics, Excellos and Charles River Laboratories share key considerations for automating a cell therapy manufacturing program at different stages of development.

Smart consumables are simplifying Point of Care (POC), and here’s what you need to know.

Michelle Duquette, Director of Business Development, Cell Therapy discusses how the closed Korus system could streamline and improve your cell and gene therapy manufacturing process from process development to GMP production.

David Hodl, Head of Business Development, Cell Therapy discusses some of the challenges the industry is facing and taking therapy development from the lab to commercial scale.

Applications Scientist Thikrayat (Tina) Al-Attar, PhD discusses the benefits of utilizing the new Korus™ technology in cell therapy manufacturing and tackling some of the current challenges in the advanced therapies industry.

Cell and gene therapy manufacturers need a supply chain that is both nimble and adaptable to sufficiently support therapeutic development

The interconnectivity of diagnostic technology is revolutionizing healthcare - but also introducing significant risk. Here’s what you need to know about diagnostic device development in the era of cybersecurity regulations.

Developing a manufacturing roadmap early on is essential when scaling cell therapy manufacturing.

Panelists from Lonza, Takeda and Vor Biopharma share their insights on how to best introduce disruptive technologies into cell therapy manufacturing processes.

Point of Care (POC) users don’t want a lab instrument. Here are 4 considerations for designing intuitive diagnostic products optimized for POC.

What product features are required for success in Point of Care (POC) diagnostics? Two executives from leading POC companies share their 4 “must-haves”.

How to navigate global supply chain challenges to help avoid cell therapy manufacturing production bottlenecks this year